查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1847866

按产品类型、应用和最终用户分類的切片检查设备市场 - 全球预测 2025-2032

Biopsy Devices Market by Product Type, Application, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 188 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，切片检查设备市场规模将达到 244.5 亿美元，复合年增长率为 11.19%。

主要市场统计数据
基准年 2024 104.6亿美元
预计年份：2025年 116.1亿美元
预测年份：2032年 244.5亿美元
复合年增长率 (%) 11.19%

这份简明扼要的切片检查设备概览涵盖了临床驱动因素、技术进步、监管环境以及领导者的采购重点。

切片检查设备在肿瘤科、肾臟科、肝病科和肺科的诊断流程中至关重要，其发展演变直接影响临床工作流程、设备应用和采购重点。目前的主要驱动因素包括技术创新融合、流程标准化以及对微创技术的日益重视，这些技术优先考虑患者舒适度和诊断效果。同时，监管机构的监管和支付方的政策也影响着设备的设计、临床证据的产生和价值论证，这些因素共同决定整个医疗保健领域的设备普及率。

随着分子诊断和新一代定序技术逐渐成为临床决策的常规组成部分，临床医生正在寻求能够缩短手术时间并提高样本品质的设备。因此，製造商正致力于研发精准的引导系统、自动化采样机制以及能够与数位病理和资料管理工具整合的平台。同时，医疗机构也在权衡资本投资与吞吐量需求，这使得生命週期成本、培训要求以及与现有影像和内视镜设备的互通性变得愈发重要。

展望未来，相关人员必须兼顾临床需求与经济现实。采购团队和临床领导者越来越要求提供受控实验室测试之外的实际疗效和营运效益证据。因此，设备开发人员和策略团队应优先考虑可靠的临床检验、以使用者为中心的设计以及能够引起临床医生和医院管理者共鸣的清晰价值主张。总而言之，这些因素共同构成了一个复杂但可行的切片检查技术创新和应用环境。

对正在重塑医疗保健环境中切片检查设备使用和检验的技术整合、自动化和不断发展的临床工作流程进行了详细的综合分析。

切片检查设备领域正经历着变革性的转变，这主要得益于影像、自动化和数据主导诊断技术的整合发展。这些趋势正在重塑切片检查的操作方式，并将其整合到诊疗流程中。影像导引标靶技术日趋成熟，能够更精准地采集较小病灶的样本，从而减少重复操作的必要性。同时，采样机制的自动化，例如精密的针头部署系统和真空辅助抽吸技术，提高了样本的完整性，降低了操作者差异，从而为后续的分子和基因组分析提供了支持。

此外，平台化思维正显着兴起，相关仪器的开发旨在与数位病理工作流程、电子健康记录系统和云端基础资料储存库进行互通。这有助于实现检体的长期追踪、诊断元元资料的整合，并支持多学科医疗团队做出复杂的治疗决策。另一个重要趋势是，出于对便利性、资源优化和流程效率的需求，越来越多的诊疗程序正从住院病房转移到门诊手术中心和诊所。

监管机构也正在适应这项技术变革，更加重视临床效用的证据和上市后监测。因此，製造商正儘早投资于临床结果研究，以开发数据收集机制，从而证明诊断信心的提高、併发症的减少以及患者吞吐量的增加。这种变革性的转变提高了临床检验和商业性准备的标准，同时也为创新创造了机会。

对2025年关税政策发展将如何重塑切片检查设备相关人员的供应链韧性、筹资策略和製造本地化的全面分析

2025年宣布或实施的关税调整的累积影响将对切片检查设备领域的采购、供应链规划和竞争定位产生复杂的多方面影响。关税有可能改变依赖跨境製造和组装的零件及成品的成本结构，尤其是那些包含来自多个司法管辖区的精密金属、聚合物和电子子系统的系统。为此，製造商正在重新评估其供应商布局、物流策略和合约条款，以降低进口关税增加带来的风险并保持价格竞争力。

临床医生和医院采购团队应重点关注总体拥有成本分析，并将关税可能导致的价格波动纳入考虑。虽然一些製造商会暂时承受关税的影响以维持市场进入，但其他製造商则会重新评估定价或将生产转移到贸易条件更有利的地区。由于供应商需要重新确认新的製造地或调整物流路线，这些调整可能会造成短期供应紧张和前置作业时间。因此，医疗机构在获取替换零件和可选医疗设备可能会面临延误，这凸显了库存计划和建立可靠服务合约的重要性。

除了营运方面的影响，关税还可能影响本地化、垂直整合和伙伴关係关係等策略决策。积极评估近岸外包、双重采购和零件标准化的企业将能够更好地管理风险并提高成本可预测性。此外，製造商和客户之间就供应连续性计划、保固影响和预期服务水准进行透明沟通至关重要。总之，2025 年关税造成的衝击不仅会影响价格，还会加速供应链和商业策略的结构性变革。

整合的细分洞察揭示了产品类型、临床应用和医疗保健环境如何相互交织，从而驱动效能需求、购买行为和发展重点。

我们深入的細項分析揭示了临床需求与设计选择的交会点，以及最大的机会所在。依产品类型划分，我们提供粗针切片系统、内视镜解决方案、细针穿刺工具和真空辅助平台。粗针切片系统提供全自动和半自动配置，兼顾操作速度和操作者控制，这些选择会影响其高效能和对复杂组织标靶的适用性。内视镜设备根据其柔性或刚性配置进行区分，这决定了其解剖结构的可及性和与现有内视镜实验室的兼容性。细针穿刺包括真空驱动和手动技术，优先考虑样本是否适用于细胞学和分子检测；而真空辅助平台则涵盖了从提供更高通量的主机解决方案到优先考虑便携性和照护现场设备。

在考虑应用时，临床优先事项因器官系统和手术入路而异。乳房应用包括诊断程序和以筛检为重点的干预措施，这要求设备能够支援高样本保真度和患者舒适度。肾臟手术可透过开放式或经皮入路进行，每种入路对设备的人体工学和针头性能都有不同的要求。肝臟取样主要透过经皮或经经子宫颈路，设备选择必须考虑血管通路和出血风险。肺部切片切片检查透过经支气管或经胸入路进行，分别需要与支气管镜引导或经皮成像相容的器械。摄护腺切片检查采用经会阴和经直肠入路，对感染控制和取样准确性的日益重视正在影响设备的偏好和临床方案。从最终用户的观点，手术在门诊手术中心、诊所、诊断实验室和医院进行，每种场所都存在一些限制，例如资本投入、人员专业水平、预期吞吐量和消毒基础设施。

整合这种细分观点，可以让相关人员根据临床工作流程和现场能力，优先考虑产品开发、培训投资和商业策略。

区域动态和招聘管道决定了美洲、欧洲、中东和非洲以及亚太地区的采购偏好、监管限制和临床优先事项。

区域动态正在塑造技术采纳模式、报销框架和监管管道，从而在美洲、欧洲、中东和非洲以及亚太地区创造差异化的商业机会。在美洲，成熟的肿瘤治疗网路和影像引导介入的广泛应用支撑了对先进采样技术的需求，而公立和私立医疗机构的支付环境则促使企业专注于可验证的价值和营运效率。政策制定者和医疗系统越来越接受能够缩短住院时间和实现门诊病人管理的创新技术，并倾向于选择适合门诊环境的设备。

在欧洲、中东和非洲，为协调监管环境和多元化的医疗保健资金筹措模式所做的努力，造就了一个错综复杂的市场格局，其中临床证据、成本效益和合规性是决定产品应用的关键因素。该地区的多个市场强调集中采购和竞标采购，这凸显了长期服务合约和具有竞争力的总成本提案的重要性。同时，在亚太地区，对诊断基础设施的快速投资、扩大专科医疗服务的覆盖范围以及不断提升的复杂实验室检测能力，推动了人们对能够提供高品质分子分析样本的设备的需求。本地製造能力和区域供应链策略也会影响设备的定价和供应，与当地经销商和契约製造合作仍然是拓展市场的有效途径。

每个地区在临床指南、培训机会和设施优先事项方面的差异，需要采取独特的市场策略，以反映当地的监管预期、报销细微差别和营运实际情况。

策略竞争格局分析，重点在于透过产品演进实现差异化，特别着重于平台整合、临床检验、客户培训和永续性。

切片检查设备产业的竞争格局日益凸显，技术卓越、强大的临床检验和全面的服务组合是胜利的关键。领先企业正投资于可升级和适应多种解剖结构的模组化平台，从而延长产品生命週期，提高医疗服务提供者的投资报酬率。与影像公司、病理实验室和数位医疗供应商的策略联盟正在建立连接样本采集和下游分析的生态系统，从而增强对综合医疗团队的价值提案。

透过客户支援和培训专案实现差异化竞争的製造商正在赢得市场青睐。此外，对永续性和设备可重复使用性的日益重视，促使企业探索材料科学创新和灭菌通讯协定，以在不损害患者安全的前提下减少对环境的影响。竞争策略还包括地理多元化、针对公共和私人支付方量身定制的定价模式，以及开发资金筹措方案以降低资本受限环境下的进入门槛。

创新发展路径体现了渐进式改进（例如人体工学和针头涂层）与颠覆性方法（例如机器人技术、即时影像处理和人工智慧辅助靶向）之间的平衡。能够证明其在改善手术效果、降低併发症发生率和简化工作流程方面具有优势的机构，将更有可能与大型医疗机构和综合医疗系统建立长期伙伴关係。

为製造商和供应商提供切实可行的策略建议，以加强临床证据、供应链韧性、客户采纳管道和互通性，从而实现永续成长。

产业领导者可以透过优先考虑以下四个策略重点，将洞察转化为可执行的计划：临床证据产生、供应链韧性、以客户为中心的商业化以及互通性。首先，投资于能够记录真实世界疗效和手术获益的全面临床研究，可以增强医保报销的论据，并支持持怀疑态度的临床医生群体接受该技术。此类工作应包括多中心观察性研究、用于收集长期疗效的註册登记，以及与病理实验室合作以证明其下游诊断价值。

其次，透过多元化、近岸外包和完善的供应商资格认证流程来增强供应链韧性，可以降低关税造成的成本转移和物流中断风险。製造商应了解关键零件的依赖关係，为关键零件维持策略性库存缓衝，并在条件允许的情况下采用双重采购模式。第三，以客户为中心的商业化需要量身定制的培训计划、灵活的资金筹措模式以及以结果为导向的服务合同，从而协调供应商和医疗服务提供者之间的奖励。强调易用性、便捷维护和快速获得技术支持，将加速设备在各种医疗环境中的应用。

最后，优先考虑与影像系统、电子健康记录和实验室资讯系统的互通性，能够为整合医疗团队创造巨大价值。开放的API、标准化的资料汇出和安全的云端连接可以促进多学科工作流程，并满足日益增长的资料驱动型诊断需求。落实这些策略支柱有助于机构降低风险、提升临床影响力并实现永续成长。

采用透明的混合方法调查方法，整合临床医师的第一手见解、技术设备审查、监管文献和情境分析，以支持可靠的结论。

调查方法结合了定性专家访谈、设备性能评估以及监管和临床文献的比较分析，建构了稳健可靠的依证。关键资讯来源包括与介入放射科医生、胸腔外科医生、乳房外科医生、病理学家和采购专业人员进行结构化讨论，以了解实际操作中的偏好、痛点和推广驱动因素。此外，也透过对设备架构、製造流程和服务模式的技术评估，将这些观点与临床需求、工程实际情况结合。

二次研究整合了同行评审的临床研究、监管文件、专业协会指南和供应商技术文檔，以检验有关样本品质、併发症发生率和设备易用性的说法。调查方法强调对关键见解和已发表的证据进行交叉检验，以减少偏差并确保结论既反映实践也反映已记录的结果。情境分析用于评估供应链对关税变化的反应，以及不同的采购模式如何影响不同医疗机构环境下的设备采用。

我们始终注重透明的采购、可复製的分析步骤以及纳入不同相关人员的声音，从而获得了可操作的见解，这些见解将引起临床医生、采购领导者和企业负责人的共鸣。

简明扼要的结论整合了技术进步、临床检验的必要性以及供应链的考量，从而确定了切片检查设备相关人员的策略重点。

总而言之，切片检查设备正处于曲折点，技术进步、临床工作流程的转变以及外部经济压力既带来了风险，也带来了机会。虽然诸如提高准确性、自动化程度和平台互通性等技术创新增强了诊断管道，但医疗服务提供者的期望和支付方的审查促使人们需要明确的临床和营运价值证据。关税政策的变化和供应链的应对措施正在加速向本地化和增强韧性的策略转变，因此，相关人员必须主动评估风险并调整采购和生产策略。

将产品开发与临床医生需求相结合、投资于严谨的疗效研究并建立适应性强的供应链的机构，将最有利于从这个不断变化的市场格局中获益。与包括影像合作伙伴、病理服务机构和医疗系统在内的整个生态系统开展合作，将进一步扩大影响力，并支持更个人化和高效的诊断管道。最终，循证创新和务实的风险缓解策略执行将决定哪些公司能够引领这个充满活力的行业。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 引入机器人切片检查平台，以提高准确性并缩短手术时间
  • 液态生物检体技术的发展使得对患者血液样本中的癌症生物标记进行非侵入性检测成为可能。
  • 开发用于细胞层面即时组织学评估的高解析度光学活检探针
  • 将人工智慧演算法整合到切片检查成像系统中，实现病灶的自动检测。
  • 改用一次性切片穿刺针，以最大限度地减少交叉感染并简化工作流程。
  • 扩展远端病理学能力，以支援远端切片检查手术咨询和诊断
  • 微波和射频消融术的出现，以及与切片检查设备相结合，实现了同时取样和治疗。

第六章美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 按产品类型切片检查设备市场

  • 粗针切片
    • 自动的
    • 半自动
  • 内视镜检查
    • 柔软的
    • 难的
  • 细针穿刺法
    • 吸
    • 手动的
  • 真空辅助
    • 基于主机
    • 手持式

第九章切片检查设备市场：依应用领域划分

  • 胸部
    • 诊断
    • 筛检
  • 肾
    • 剖腹手术
    • 经皮
  • 肝
    • 经皮
    • 经颈静脉
  • 肺
    • 经支气管
    • 经胸
  • 摄护腺
    • 经会阴
    • 经直肠

第十章 按最终用户分類的切片检查设备市场

  • 门诊手术中心
  • 诊所
  • 诊断实验室
  • 医院

第十一章 各地区切片检查设备市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十二章 按组别分類的切片检查设备市场

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十三章 各国切片检查设备市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十四章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • Hologic, Inc.
    • Becton, Dickinson and Company
    • Boston Scientific Corporation
    • Olympus Corporation
    • Cook Incorporated
    • Argon Medical Devices, Inc.
    • Merit Medical Systems, Inc.
    • Teleflex Incorporated
    • Medtronic plc
    • Ethicon Inc.
Product Code: MRR-4103B31E073F

The Biopsy Devices Market is projected to grow by USD 24.45 billion at a CAGR of 11.19% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 10.46 billion
Estimated Year [2025] USD 11.61 billion
Forecast Year [2032] USD 24.45 billion
CAGR (%) 11.19%

Concise foundational overview of biopsy device landscape capturing clinical drivers, technological advances, regulatory influences, and procurement priorities for leaders

Biopsy devices are central to diagnostic pathways across oncology, nephrology, hepatology, and pulmonary medicine, and their evolution directly shapes clinical workflows, device adoption, and procurement priorities. Contemporary drivers include a convergence of technological innovation, procedural standardization, and an increasing focus on minimally invasive techniques that prioritize patient comfort and diagnostic yield. In parallel, regulatory scrutiny and payer policies are influencing device design, clinical evidence generation, and value demonstration, which together determine adoption speed across care settings.

Clinicians are demanding devices that reduce procedure time while enhancing sample quality, particularly as molecular diagnostics and next-generation sequencing become routine components of clinical decision-making. As a result, manufacturers are directing development toward precision-guided systems, automation of sampling mechanisms, and platforms that integrate with digital pathology and data management tools. At the same time, providers are balancing capital investment with throughput needs, which elevates the importance of lifecycle costs, training requirements, and interoperability with existing imaging and endoscopy suites.

Moving forward, stakeholders must reconcile clinical imperatives with economic realities. Procurement teams and clinical leaders are increasingly looking for evidence of real-world effectiveness and operational benefits beyond controlled trials. Therefore, device developers and strategy teams should prioritize robust clinical validation, user-centered design, and clear value narratives that resonate with both proceduralists and hospital administrators. Taken together, these elements create a complex but actionable landscape for innovation and adoption in biopsy technologies.

Detailed synthesis of technological convergence, automation, and clinical workflow evolution that is reshaping biopsy device utilization and validation across care settings

The biopsy device landscape is undergoing transformative shifts driven by converging advances in imaging, automation, and data-driven diagnostics, and these trends are reshaping how biopsies are performed and integrated into care pathways. Image-guided targeting has matured, enabling more accurate sampling of smaller lesions and reducing the need for repeat procedures. Concurrently, automation in sampling mechanics, such as refined needle deployment systems and vacuum-assisted extraction, is improving sample integrity and reducing operator variability, which in turn supports downstream molecular and genomic analyses.

Additionally, there is a noticeable shift toward platform thinking, where devices are developed to interoperate with digital pathology workflows, electronic health record systems, and cloud-based data repositories. This facilitates longitudinal tracking of samples, integration of diagnostic metadata, and support for multidisciplinary care teams making complex treatment decisions. Another important dynamic is the movement of procedures from inpatient wards to ambulatory surgical centers and clinic-based settings, driven by demand for convenience, resource optimization, and procedural efficiency.

Regulatory pathways are adapting to these technological shifts, emphasizing evidence of clinical utility and post-market surveillance. As a result, manufacturers are investing earlier in clinical outcomes studies and in building data capture mechanisms that demonstrate improved diagnostic confidence, reduced complications, and enhanced patient throughput. Taken together, these transformative shifts create opportunities for innovation while raising the bar for clinical validation and commercial readiness.

Comprehensive analysis of how 2025 tariff developments are reshaping supply chain resilience, procurement strategies, and manufacturing localization for biopsy device stakeholders

The cumulative impact of tariff policy changes announced or implemented in 2025 introduces a layer of complexity for procurement, supply chain planning, and competitive positioning in the biopsy device arena. Tariffs can alter cost structures for components and finished devices that rely on cross-border manufacturing and assembly, particularly for systems incorporating precision metals, polymers, and electronic subsystems sourced from multiple jurisdictions. In response, manufacturers are reassessing supplier footprints, logistics strategies, and contractual terms to mitigate exposure to incremental import duties and to preserve pricing competitiveness.

Clinicians and hospital procurement teams should expect an emphasis on total cost of ownership analyses that account for potential tariff-driven price volatility. Some manufacturers may absorb tariff impacts temporarily to maintain market access, whereas others will recalibrate pricing or shift production to locations with more favorable trade terms. These adjustments can create short-term supply constraints or lead times as suppliers requalify new manufacturing sites or reroute logistics. In turn, providers may face delays in obtaining replacement parts or elective devices, which underscores the importance of inventory planning and of establishing reliable service agreements.

Beyond operational effects, tariffs can influence strategic decisions around localization, vertical integration, and partnerships. Organizations that proactively evaluate nearshoring, dual sourcing, or component standardization will better manage risk and cost predictability. Furthermore, transparent communication between manufacturers and customers about supply continuity plans, warranty implications, and service-level expectations becomes critical. In sum, tariff-induced perturbations in 2025 will not only affect pricing but also accelerate structural shifts across supply chains and commercial strategies.

Integrated segmentation insights revealing how product types, clinical applications, and care settings converge to define performance needs, purchasing behavior, and development priorities

Insightful segmentation analysis clarifies where clinical needs intersect with design choices and where commercial opportunities are most concentrated. By product type, the landscape spans core needle systems, endoscopic solutions, fine needle aspiration tools, and vacuum-assisted platforms. Core needle systems include both automatic and semi-automatic variants that balance deployment speed with operator control, and these choices influence suitability across high-throughput and complex tissue targets. Endoscopic devices are differentiated by flexible and rigid configurations, which determine accessibility to anatomical sites and compatibility with existing endoscopy suites. Fine needle aspiration encompasses aspiration-driven and manual techniques that prioritize sample adequacy for cytology and molecular assays, while vacuum-assisted platforms range from console-based solutions offering higher throughput to handheld devices that favor portability and point-of-care use.

When considering application, clinical priorities vary by organ system and by the procedural approach used. Breast applications include diagnostic procedures and screening-focused interventions, requiring devices that support high sample fidelity and patient comfort. Kidney procedures are performed via open or percutaneous approaches, each imposing distinct device ergonomics and needle performance needs. Liver sampling is primarily percutaneous or transjugular, and device selection must account for vascular access considerations and bleeding risk. Lung biopsies executed via transbronchial or transthoracic routes demand tools compatible with bronchoscopic guidance or percutaneous imaging, respectively. Prostate procedures employ transperineal and transrectal approaches, and the growing emphasis on infection control and sampling accuracy is affecting device preference and clinical protocols. From an end-user perspective, procedures occur across ambulatory surgical centers, clinics, diagnostic laboratories, and hospitals, and each setting imposes constraints around capital expenditure, staffing expertise, throughput expectations, and sterilization infrastructure.

Integrating these segmentation perspectives enables stakeholders to prioritize product development, training investments, and commercial strategies that are aligned with clinical workflows and institutional capabilities.

Regional dynamics and adoption pathways that define procurement preferences, regulatory constraints, and clinical priorities across the Americas, Europe Middle East & Africa, and Asia-Pacific geographies

Regional dynamics shape adoption patterns, reimbursement frameworks, and regulatory pathways, creating differentiated opportunities across the Americas, Europe, Middle East & Africa, and Asia-Pacific regions. In the Americas, mature oncology care networks and widespread adoption of image-guided interventions support demand for advanced sampling technologies, while private and public payer environments drive a focus on demonstrable value and operational efficiency. Policymakers and health systems are increasingly receptive to innovations that reduce hospital stays and enable outpatient management, which favors devices compatible with ambulatory settings.

In Europe, Middle East & Africa, regulatory harmonization efforts and diverse healthcare financing models create a nuanced landscape where clinical evidence, cost-effectiveness, and compliance are key determinants of uptake. Several markets in this region emphasize centralized procurement and tender-based purchasing, which elevates the importance of long-term service agreements and competitive total cost propositions. Meanwhile, in the Asia-Pacific region, rapid investments in diagnostic infrastructure, expanding access to specialist care, and growing capacity for complex laboratory testing are stimulating interest in devices that deliver high-quality samples for molecular analysis. Local manufacturing capabilities and regional supply chain strategies also influence device pricing and availability, and partnerships with local distributors or contract manufacturers remain a pragmatic route to market expansion.

Across all regions, differences in clinical guidelines, training availability, and institutional priorities require tailored market approaches that reflect local regulatory expectations, reimbursement nuances, and operational realities.

Strategic competitor landscape analysis highlighting differentiation through platform integration, clinical validation, customer training, and sustainability-driven product evolution

Competitive positioning within the biopsy device landscape is increasingly determined by the ability to pair engineering excellence with robust clinical validation and comprehensive service offerings. Leading firms are investing in modular platforms that can be upgraded or adapted for multiple anatomical targets, which extends product lifecycles and enhances return on investment for providers. Strategic collaborations with imaging companies, pathology labs, and digital health vendors are creating ecosystems that link sample acquisition to downstream analytics, thereby strengthening value propositions for integrated care teams.

Manufacturers differentiating through customer support and training programs are gaining market preference, since procedural success and device utilization are tightly linked to operator proficiency. Additionally, a growing emphasis on sustainability and device reusability is prompting companies to explore materials science innovations and sterilization protocols that reduce environmental impact without compromising patient safety. Competitive strategies also include geographic diversification, selective pricing models tailored to public and private payers, and the development of financing arrangements that lower barriers to adoption in capital-constrained settings.

Innovation pipelines reflect a balance between incremental improvements-such as ergonomics and needle coatings-and disruptive approaches that combine robotics, real-time imaging, and AI-assisted targeting. Organizations that can demonstrate improved procedural outcomes, reduced complication rates, and streamlined workflows are well positioned to secure long-term partnerships with high-volume providers and integrated health systems.

Actionable strategic recommendations for manufacturers and providers to fortify clinical evidence, supply chain resilience, customer adoption pathways, and interoperability for sustained growth

Industry leaders can translate insights into actionable plans by prioritizing four strategic thrusts: clinical evidence generation, supply chain resilience, customer-centric commercialization, and interoperability. First, investing in comprehensive clinical studies that document real-world effectiveness and procedural advantages will strengthen reimbursement discussions and support adoption among skeptical clinician groups. These efforts should include multicenter observational studies, registries that capture longitudinal outcomes, and collaborations with pathology labs to demonstrate downstream diagnostic value.

Second, strengthening supply chain resilience through diversification, nearshoring, and robust supplier qualification processes will reduce exposure to tariff-driven cost shifts and logistical disruptions. Manufacturers should map critical component dependencies, maintain strategic inventory buffers for key parts, and pursue dual sourcing where feasible. Third, customer-centric commercialization requires tailored training programs, flexible financing models, and outcome-focused service agreements that align incentives between vendors and providers. Emphasizing ease of use, maintenance simplicity, and rapid access to technical support will accelerate device adoption across diverse care settings.

Finally, prioritizing interoperability with imaging systems, electronic health records, and laboratory information systems will create compelling value for integrated care teams. Open APIs, standardized data exports, and secure cloud connectivity can facilitate multidisciplinary workflows and support the growing demand for data-driven diagnostics. By executing on these strategic pillars, organizations can reduce risk, enhance clinical impact, and achieve sustainable growth.

Transparent mixed-methods research methodology integrating primary clinician insights, technical device reviews, regulatory literature, and scenario analysis to support robust conclusions

The research approach combines qualitative expert interviews, device performance reviews, and comparative analysis of regulatory and clinical literature to create a robust and defensible evidence base. Primary inputs included structured discussions with interventional radiologists, thoracic and breast surgeons, pathologists, and procurement professionals to capture real-world procedural preferences, pain points, and adoption drivers. These perspectives were contextualized with technical assessments of device architectures, manufacturing considerations, and service models to align clinical needs with engineering realities.

Secondary research synthesized peer-reviewed clinical studies, regulatory filings, guidelines from professional societies, and supplier technical documents to validate claims related to sample quality, complication rates, and device usability. The methodology emphasized cross-validation between primary insights and published evidence to reduce bias and to ensure that conclusions reflect both practice and documented outcomes. Scenario analysis was used to evaluate supply chain responses to tariff changes and to assess how varying procurement models influence adoption in different institutional settings.

Throughout, the emphasis was on transparent sourcing, reproducible analytic steps, and the inclusion of diverse stakeholder voices to produce actionable findings that resonate with clinicians, procurement leaders, and corporate strategists.

Concise conclusion synthesizing technological progress, clinical validation imperatives, and supply chain considerations that define strategic priorities for biopsy device stakeholders

In sum, biopsy devices are at an inflection point where technological advancements, changing clinical workflows, and external economic pressures converge to create both risk and opportunity. Innovations in targeting accuracy, automation, and platform interoperability are enhancing diagnostic pathways, while provider expectations and payer scrutiny are elevating the need for clear evidence of clinical and operational value. Tariff developments and supply chain responses are accelerating strategic shifts toward localization and resilience, making it imperative for stakeholders to proactively assess risks and adjust procurement and manufacturing strategies.

Organizations that align product development with clinician needs, invest in rigorous outcomes research, and build adaptable supply chains will be best positioned to capture the benefits of this evolving landscape. Collaboration across the ecosystem-including imaging partners, pathology services, and health systems-will further amplify impact and support more personalized and efficient diagnostic pathways. Ultimately, pragmatic execution of evidence-driven innovation and risk mitigation strategies will determine who leads in this dynamic sector.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Adoption of robotic-assisted biopsy platforms to enhance precision and reduce procedure time
  • 5.2. Growth of liquid biopsy technologies enabling non-invasive detection of cancer biomarkers in patient blood samples
  • 5.3. Development of high-definition optical biopsy probes for real-time histological assessment at the cellular level
  • 5.4. Integration of artificial intelligence algorithms in biopsy imaging systems for automated lesion detection
  • 5.5. Shift toward single-use disposable biopsy needles to minimize cross-contamination and streamline workflow
  • 5.6. Expansion of telepathology capabilities to support remote biopsy procedure consultations and diagnostics
  • 5.7. Emergence of microwave and radiofrequency ablation integrated with biopsy devices for simultaneous sampling and therapy

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Biopsy Devices Market, by Product Type

  • 8.1. Core Needle
    • 8.1.1. Automatic
    • 8.1.2. Semi Automatic
  • 8.2. Endoscopic
    • 8.2.1. Flexible
    • 8.2.2. Rigid
  • 8.3. Fine Needle Aspiration
    • 8.3.1. Aspiration
    • 8.3.2. Manual
  • 8.4. Vacuum Assisted
    • 8.4.1. Console Based
    • 8.4.2. Handheld

9. Biopsy Devices Market, by Application

  • 9.1. Breast
    • 9.1.1. Diagnostic
    • 9.1.2. Screening
  • 9.2. Kidney
    • 9.2.1. Open
    • 9.2.2. Percutaneous
  • 9.3. Liver
    • 9.3.1. Percutaneous
    • 9.3.2. Transjugular
  • 9.4. Lung
    • 9.4.1. Transbronchial
    • 9.4.2. Transthoracic
  • 9.5. Prostate
    • 9.5.1. Transperineal
    • 9.5.2. Transrectal

10. Biopsy Devices Market, by End User

  • 10.1. Ambulatory Surgical Centers
  • 10.2. Clinics
  • 10.3. Diagnostic Laboratories
  • 10.4. Hospitals

11. Biopsy Devices Market, by Region

  • 11.1. Americas
    • 11.1.1. North America
    • 11.1.2. Latin America
  • 11.2. Europe, Middle East & Africa
    • 11.2.1. Europe
    • 11.2.2. Middle East
    • 11.2.3. Africa
  • 11.3. Asia-Pacific

12. Biopsy Devices Market, by Group

  • 12.1. ASEAN
  • 12.2. GCC
  • 12.3. European Union
  • 12.4. BRICS
  • 12.5. G7
  • 12.6. NATO

13. Biopsy Devices Market, by Country

  • 13.1. United States
  • 13.2. Canada
  • 13.3. Mexico
  • 13.4. Brazil
  • 13.5. United Kingdom
  • 13.6. Germany
  • 13.7. France
  • 13.8. Russia
  • 13.9. Italy
  • 13.10. Spain
  • 13.11. China
  • 13.12. India
  • 13.13. Japan
  • 13.14. Australia
  • 13.15. South Korea

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2024
  • 14.2. FPNV Positioning Matrix, 2024
  • 14.3. Competitive Analysis
    • 14.3.1. Hologic, Inc.
    • 14.3.2. Becton, Dickinson and Company
    • 14.3.3. Boston Scientific Corporation
    • 14.3.4. Olympus Corporation
    • 14.3.5. Cook Incorporated
    • 14.3.6. Argon Medical Devices, Inc.
    • 14.3.7. Merit Medical Systems, Inc.
    • 14.3.8. Teleflex Incorporated
    • 14.3.9. Medtronic plc
    • 14.3.10. Ethicon Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL BIOPSY DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL BIOPSY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL BIOPSY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL BIOPSY DEVICES MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL BIOPSY DEVICES MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL BIOPSY DEVICES MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL BIOPSY DEVICES MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL BIOPSY DEVICES MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 9. AMERICAS BIOPSY DEVICES MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. NORTH AMERICA BIOPSY DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. LATIN AMERICA BIOPSY DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. EUROPE, MIDDLE EAST & AFRICA BIOPSY DEVICES MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. EUROPE BIOPSY DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. MIDDLE EAST BIOPSY DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. AFRICA BIOPSY DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC BIOPSY DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. GLOBAL BIOPSY DEVICES MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASEAN BIOPSY DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GCC BIOPSY DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. EUROPEAN UNION BIOPSY DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. BRICS BIOPSY DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. G7 BIOPSY DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. NATO BIOPSY DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. GLOBAL BIOPSY DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BIOPSY DEVICES MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 26. BIOPSY DEVICES MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. BIOPSY DEVICES MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL BIOPSY DEVICES MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL BIOPSY DEVICES MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL BIOPSY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL BIOPSY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL BIOPSY DEVICES MARKET SIZE, BY CORE NEEDLE, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL BIOPSY DEVICES MARKET SIZE, BY CORE NEEDLE, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL BIOPSY DEVICES MARKET SIZE, BY CORE NEEDLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL BIOPSY DEVICES MARKET SIZE, BY CORE NEEDLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL BIOPSY DEVICES MARKET SIZE, BY CORE NEEDLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL BIOPSY DEVICES MARKET SIZE, BY CORE NEEDLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL BIOPSY DEVICES MARKET SIZE, BY CORE NEEDLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL BIOPSY DEVICES MARKET SIZE, BY CORE NEEDLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL BIOPSY DEVICES MARKET SIZE, BY AUTOMATIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL BIOPSY DEVICES MARKET SIZE, BY AUTOMATIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL BIOPSY DEVICES MARKET SIZE, BY AUTOMATIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL BIOPSY DEVICES MARKET SIZE, BY AUTOMATIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL BIOPSY DEVICES MARKET SIZE, BY AUTOMATIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL BIOPSY DEVICES MARKET SIZE, BY AUTOMATIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL BIOPSY DEVICES MARKET SIZE, BY SEMI AUTOMATIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL BIOPSY DEVICES MARKET SIZE, BY SEMI AUTOMATIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL BIOPSY DEVICES MARKET SIZE, BY SEMI AUTOMATIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL BIOPSY DEVICES MARKET SIZE, BY SEMI AUTOMATIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL BIOPSY DEVICES MARKET SIZE, BY SEMI AUTOMATIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL BIOPSY DEVICES MARKET SIZE, BY SEMI AUTOMATIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL BIOPSY DEVICES MARKET SIZE, BY ENDOSCOPIC, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL BIOPSY DEVICES MARKET SIZE, BY ENDOSCOPIC, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL BIOPSY DEVICES MARKET SIZE, BY ENDOSCOPIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL BIOPSY DEVICES MARKET SIZE, BY ENDOSCOPIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL BIOPSY DEVICES MARKET SIZE, BY ENDOSCOPIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL BIOPSY DEVICES MARKET SIZE, BY ENDOSCOPIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL BIOPSY DEVICES MARKET SIZE, BY ENDOSCOPIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL BIOPSY DEVICES MARKET SIZE, BY ENDOSCOPIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL BIOPSY DEVICES MARKET SIZE, BY FLEXIBLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL BIOPSY DEVICES MARKET SIZE, BY FLEXIBLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL BIOPSY DEVICES MARKET SIZE, BY FLEXIBLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL BIOPSY DEVICES MARKET SIZE, BY FLEXIBLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL BIOPSY DEVICES MARKET SIZE, BY FLEXIBLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL BIOPSY DEVICES MARKET SIZE, BY FLEXIBLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL BIOPSY DEVICES MARKET SIZE, BY RIGID, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL BIOPSY DEVICES MARKET SIZE, BY RIGID, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL BIOPSY DEVICES MARKET SIZE, BY RIGID, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL BIOPSY DEVICES MARKET SIZE, BY RIGID, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL BIOPSY DEVICES MARKET SIZE, BY RIGID, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL BIOPSY DEVICES MARKET SIZE, BY RIGID, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL BIOPSY DEVICES MARKET SIZE, BY FINE NEEDLE ASPIRATION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL BIOPSY DEVICES MARKET SIZE, BY FINE NEEDLE ASPIRATION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL BIOPSY DEVICES MARKET SIZE, BY FINE NEEDLE ASPIRATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL BIOPSY DEVICES MARKET SIZE, BY FINE NEEDLE ASPIRATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL BIOPSY DEVICES MARKET SIZE, BY FINE NEEDLE ASPIRATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL BIOPSY DEVICES MARKET SIZE, BY FINE NEEDLE ASPIRATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL BIOPSY DEVICES MARKET SIZE, BY FINE NEEDLE ASPIRATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL BIOPSY DEVICES MARKET SIZE, BY FINE NEEDLE ASPIRATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL BIOPSY DEVICES MARKET SIZE, BY ASPIRATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL BIOPSY DEVICES MARKET SIZE, BY ASPIRATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL BIOPSY DEVICES MARKET SIZE, BY ASPIRATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL BIOPSY DEVICES MARKET SIZE, BY ASPIRATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL BIOPSY DEVICES MARKET SIZE, BY ASPIRATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL BIOPSY DEVICES MARKET SIZE, BY ASPIRATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL BIOPSY DEVICES MARKET SIZE, BY MANUAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL BIOPSY DEVICES MARKET SIZE, BY MANUAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL BIOPSY DEVICES MARKET SIZE, BY MANUAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL BIOPSY DEVICES MARKET SIZE, BY MANUAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL BIOPSY DEVICES MARKET SIZE, BY MANUAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL BIOPSY DEVICES MARKET SIZE, BY MANUAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL BIOPSY DEVICES MARKET SIZE, BY VACUUM ASSISTED, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL BIOPSY DEVICES MARKET SIZE, BY VACUUM ASSISTED, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL BIOPSY DEVICES MARKET SIZE, BY VACUUM ASSISTED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL BIOPSY DEVICES MARKET SIZE, BY VACUUM ASSISTED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL BIOPSY DEVICES MARKET SIZE, BY VACUUM ASSISTED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL BIOPSY DEVICES MARKET SIZE, BY VACUUM ASSISTED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL BIOPSY DEVICES MARKET SIZE, BY VACUUM ASSISTED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL BIOPSY DEVICES MARKET SIZE, BY VACUUM ASSISTED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL BIOPSY DEVICES MARKET SIZE, BY CONSOLE BASED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL BIOPSY DEVICES MARKET SIZE, BY CONSOLE BASED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL BIOPSY DEVICES MARKET SIZE, BY CONSOLE BASED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL BIOPSY DEVICES MARKET SIZE, BY CONSOLE BASED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL BIOPSY DEVICES MARKET SIZE, BY CONSOLE BASED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL BIOPSY DEVICES MARKET SIZE, BY CONSOLE BASED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL BIOPSY DEVICES MARKET SIZE, BY HANDHELD, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL BIOPSY DEVICES MARKET SIZE, BY HANDHELD, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL BIOPSY DEVICES MARKET SIZE, BY HANDHELD, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL BIOPSY DEVICES MARKET SIZE, BY HANDHELD, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL BIOPSY DEVICES MARKET SIZE, BY HANDHELD, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL BIOPSY DEVICES MARKET SIZE, BY HANDHELD, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL BIOPSY DEVICES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL BIOPSY DEVICES MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL BIOPSY DEVICES MARKET SIZE, BY BREAST, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL BIOPSY DEVICES MARKET SIZE, BY BREAST, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL BIOPSY DEVICES MARKET SIZE, BY BREAST, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL BIOPSY DEVICES MARKET SIZE, BY BREAST, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL BIOPSY DEVICES MARKET SIZE, BY BREAST, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL BIOPSY DEVICES MARKET SIZE, BY BREAST, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL BIOPSY DEVICES MARKET SIZE, BY BREAST, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL BIOPSY DEVICES MARKET SIZE, BY BREAST, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL BIOPSY DEVICES MARKET SIZE, BY DIAGNOSTIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL BIOPSY DEVICES MARKET SIZE, BY DIAGNOSTIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL BIOPSY DEVICES MARKET SIZE, BY DIAGNOSTIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL BIOPSY DEVICES MARKET SIZE, BY DIAGNOSTIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL BIOPSY DEVICES MARKET SIZE, BY DIAGNOSTIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL BIOPSY DEVICES MARKET SIZE, BY DIAGNOSTIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL BIOPSY DEVICES MARKET SIZE, BY SCREENING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL BIOPSY DEVICES MARKET SIZE, BY SCREENING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL BIOPSY DEVICES MARKET SIZE, BY SCREENING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL BIOPSY DEVICES MARKET SIZE, BY SCREENING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL BIOPSY DEVICES MARKET SIZE, BY SCREENING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL BIOPSY DEVICES MARKET SIZE, BY SCREENING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL BIOPSY DEVICES MARKET SIZE, BY KIDNEY, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL BIOPSY DEVICES MARKET SIZE, BY KIDNEY, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL BIOPSY DEVICES MARKET SIZE, BY KIDNEY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL BIOPSY DEVICES MARKET SIZE, BY KIDNEY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL BIOPSY DEVICES MARKET SIZE, BY KIDNEY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL BIOPSY DEVICES MARKET SIZE, BY KIDNEY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL BIOPSY DEVICES MARKET SIZE, BY KIDNEY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL BIOPSY DEVICES MARKET SIZE, BY KIDNEY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL BIOPSY DEVICES MARKET SIZE, BY OPEN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL BIOPSY DEVICES MARKET SIZE, BY OPEN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL BIOPSY DEVICES MARKET SIZE, BY OPEN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL BIOPSY DEVICES MARKET SIZE, BY OPEN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL BIOPSY DEVICES MARKET SIZE, BY OPEN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL BIOPSY DEVICES MARKET SIZE, BY OPEN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL BIOPSY DEVICES MARKET SIZE, BY PERCUTANEOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL BIOPSY DEVICES MARKET SIZE, BY PERCUTANEOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL BIOPSY DEVICES MARKET SIZE, BY PERCUTANEOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL BIOPSY DEVICES MARKET SIZE, BY PERCUTANEOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL BIOPSY DEVICES MARKET SIZE, BY PERCUTANEOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL BIOPSY DEVICES MARKET SIZE, BY PERCUTANEOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL BIOPSY DEVICES MARKET SIZE, BY LIVER, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL BIOPSY DEVICES MARKET SIZE, BY LIVER, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL BIOPSY DEVICES MARKET SIZE, BY LIVER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL BIOPSY DEVICES MARKET SIZE, BY LIVER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL BIOPSY DEVICES MARKET SIZE, BY LIVER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL BIOPSY DEVICES MARKET SIZE, BY LIVER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL BIOPSY DEVICES MARKET SIZE, BY LIVER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL BIOPSY DEVICES MARKET SIZE, BY LIVER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL BIOPSY DEVICES MARKET SIZE, BY PERCUTANEOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL BIOPSY DEVICES MARKET SIZE, BY PERCUTANEOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL BIOPSY DEVICES MARKET SIZE, BY PERCUTANEOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL BIOPSY DEVICES MARKET SIZE, BY PERCUTANEOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL BIOPSY DEVICES MARKET SIZE, BY PERCUTANEOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL BIOPSY DEVICES MARKET SIZE, BY PERCUTANEOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL BIOPSY DEVICES MARKET SIZE, BY TRANSJUGULAR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL BIOPSY DEVICES MARKET SIZE, BY TRANSJUGULAR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL BIOPSY DEVICES MARKET SIZE, BY TRANSJUGULAR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL BIOPSY DEVICES MARKET SIZE, BY TRANSJUGULAR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL BIOPSY DEVICES MARKET SIZE, BY TRANSJUGULAR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL BIOPSY DEVICES MARKET SIZE, BY TRANSJUGULAR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL BIOPSY DEVICES MARKET SIZE, BY LUNG, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL BIOPSY DEVICES MARKET SIZE, BY LUNG, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL BIOPSY DEVICES MARKET SIZE, BY LUNG, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL BIOPSY DEVICES MARKET SIZE, BY LUNG, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL BIOPSY DEVICES MARKET SIZE, BY LUNG, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL BIOPSY DEVICES MARKET SIZE, BY LUNG, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL BIOPSY DEVICES MARKET SIZE, BY LUNG, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL BIOPSY DEVICES MARKET SIZE, BY LUNG, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL BIOPSY DEVICES MARKET SIZE, BY TRANSBRONCHIAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL BIOPSY DEVICES MARKET SIZE, BY TRANSBRONCHIAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL BIOPSY DEVICES MARKET SIZE, BY TRANSBRONCHIAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL BIOPSY DEVICES MARKET SIZE, BY TRANSBRONCHIAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL BIOPSY DEVICES MARKET SIZE, BY TRANSBRONCHIAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL BIOPSY DEVICES MARKET SIZE, BY TRANSBRONCHIAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL BIOPSY DEVICES MARKET SIZE, BY TRANSTHORACIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL BIOPSY DEVICES MARKET SIZE, BY TRANSTHORACIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL BIOPSY DEVICES MARKET SIZE, BY TRANSTHORACIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL BIOPSY DEVICES MARKET SIZE, BY TRANSTHORACIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL BIOPSY DEVICES MARKET SIZE, BY TRANSTHORACIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL BIOPSY DEVICES MARKET SIZE, BY TRANSTHORACIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL BIOPSY DEVICES MARKET SIZE, BY PROSTATE, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL BIOPSY DEVICES MARKET SIZE, BY PROSTATE, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL BIOPSY DEVICES MARKET SIZE, BY PROSTATE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL BIOPSY DEVICES MARKET SIZE, BY PROSTATE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL BIOPSY DEVICES MARKET SIZE, BY PROSTATE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL BIOPSY DEVICES MARKET SIZE, BY PROSTATE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL BIOPSY DEVICES MARKET SIZE, BY PROSTATE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL BIOPSY DEVICES MARKET SIZE, BY PROSTATE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL BIOPSY DEVICES MARKET SIZE, BY TRANSPERINEAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL BIOPSY DEVICES MARKET SIZE, BY TRANSPERINEAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL BIOPSY DEVICES MARKET SIZE, BY TRANSPERINEAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL BIOPSY DEVICES MARKET SIZE, BY TRANSPERINEAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL BIOPSY DEVICES MARKET SIZE, BY TRANSPERINEAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL BIOPSY DEVICES MARKET SIZE, BY TRANSPERINEAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL BIOPSY DEVICES MARKET SIZE, BY TRANSRECTAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL BIOPSY DEVICES MARKET SIZE, BY TRANSRECTAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL BIOPSY DEVICES MARKET SIZE, BY TRANSRECTAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL BIOPSY DEVICES MARKET SIZE, BY TRANSRECTAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL BIOPSY DEVICES MARKET SIZE, BY TRANSRECTAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL BIOPSY DEVICES MARKET SIZE, BY TRANSRECTAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL BIOPSY DEVICES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL BIOPSY DEVICES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL BIOPSY DEVICES MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL BIOPSY DEVICES MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL BIOPSY DEVICES MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL BIOPSY DEVICES MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL BIOPSY DEVICES MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL BIOPSY DEVICES MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL BIOPSY DEVICES MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL BIOPSY DEVICES MARKET SIZE, BY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL BIOPSY DEVICES MARKET SIZE, BY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL BIOPSY DEVICES MARKET SIZE, BY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL BIOPSY DEVICES MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL BIOPSY DEVICES MARKET SIZE, BY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL BIOPSY DEVICES MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL BIOPSY DEVICES MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL BIOPSY DEVICES MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL BIOPSY DEVICES MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL BIOPSY DEVICES MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL BIOPSY DEVICES MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL BIOPSY DEVICES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL BIOPSY DEVICES MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL BIOPSY DEVICES MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL BIOPSY DEVICES MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL BIOPSY DEVICES MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL BIOPSY DEVICES MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL BIOPSY DEVICES MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL BIOPSY DEVICES MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 217. AMERICAS BIOPSY DEVICES MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 218. AMERICAS BIOPSY DEVICES MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 219. AMERICAS BIOPSY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 220. AMERICAS BIOPSY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 221. AMERICAS BIOPSY DEVICES MARKET SIZE, BY CORE NEEDLE, 2018-2024 (USD MILLION)
  • TABLE 222. AMERICAS BIOPSY DEVICES MARKET SIZE, BY CORE NEEDLE, 2025-2032 (USD MILLION)
  • TABLE 223. AMERICAS BIOPSY DEVICES MARKET SIZE, BY ENDOSCOPIC, 2018-2024 (USD MILLION)
  • TABLE 224. AMERICAS BIOPSY DEVICES MARKET SIZE, BY ENDOSCOPIC, 2025-2032 (USD MILLION)
  • TABLE 225. AMERICAS BIOPSY DEVICES MARKET SIZE, BY FINE NEEDLE ASPIRATION, 2018-2024 (USD MILLION)
  • TABLE 226. AMERICAS BIOPSY DEVICES MARKET SIZE, BY FINE NEEDLE ASPIRATION, 2025-2032 (USD MILLION)
  • TABLE 227. AMERICAS BIOPSY DEVICES MARKET SIZE, BY VACUUM ASSISTED, 2018-2024 (USD MILLION)
  • TABLE 228. AMERICAS BIOPSY DEVICES MARKET SIZE, BY VACUUM ASSISTED, 2025-2032 (USD MILLION)
  • TABLE 229. AMERICAS BIOPSY DEVICES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 230. AMERICAS BIOPSY DEVICES MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 231. AMERICAS BIOPSY DEVICES MARKET SIZE, BY BREAST, 2018-2024 (USD MILLION)
  • TABLE 232. AMERICAS BIOPSY DEVICES MARKET SIZE, BY BREAST, 2025-2032 (USD MILLION)
  • TABLE 233. AMERICAS BIOPSY DEVICES MARKET SIZE, BY KIDNEY, 2018-2024 (USD MILLION)
  • TABLE 234. AMERICAS BIOPSY DEVICES MARKET SIZE, BY KIDNEY, 2025-2032 (USD MILLION)
  • TABLE 235. AMERICAS BIOPSY DEVICES MARKET SIZE, BY LIVER, 2018-2024 (USD MILLION)
  • TABLE 236. AMERICAS BIOPSY DEVICES MARKET SIZE, BY LIVER, 2025-2032 (USD MILLION)
  • TABLE 237. AMERICAS BIOPSY DEVICES MARKET SIZE, BY LUNG, 2018-2024 (USD MILLION)
  • TABLE 238. AMERICAS BIOPSY DEVICES MARKET SIZE, BY LUNG, 2025-2032 (USD MILLION)
  • TABLE 239. AMERICAS BIOPSY DEVICES MARKET SIZE, BY PROSTATE, 2018-2024 (USD MILLION)
  • TABLE 240. AMERICAS BIOPSY DEVICES MARKET SIZE, BY PROSTATE, 2025-2032 (USD MILLION)
  • TABLE 241. AMERICAS BIOPSY DEVICES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 242. AMERICAS BIOPSY DEVICES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 243. NORTH AMERICA BIOPSY DEVICES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 244. NORTH AMERICA BIOPSY DEVICES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 245. NORTH AMERICA BIOPSY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 246. NORTH AMERICA BIOPSY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 247. NORTH AMERICA BIOPSY DEVICES MARKET SIZE, BY CORE NEEDLE, 2018-2024 (USD MILLION)
  • TABLE 248. NORTH AMERICA BIOPSY DEVICES MARKET SIZE, BY CORE NEEDLE, 2025-2032 (USD MILLION)
  • TABLE 249. NORTH AMERICA BIOPSY DEVICES MARKET SIZE, BY ENDOSCOPIC, 2018-2024 (USD MILLION)
  • TABLE 250. NORTH AMERICA BIOPSY DEVICES MARKET SIZE, BY ENDOSCOPIC, 2025-2032 (USD MILLION)
  • TABLE 251. NORTH AMERICA BIOPSY DEVICES MARKET SIZE, BY FINE NEEDLE ASPIRATION, 2018-2024 (USD MILLION)
  • TABLE 252. NORTH AMERICA BIOPSY DEVICES MARKET SIZE, BY FINE NEEDLE ASPIRATION, 2025-2032 (USD MILLION)
  • TABLE 253. NORTH AMERICA BIOPSY DEVICES MARKET SIZE, BY VACUUM ASSISTED, 2018-2024 (USD MILLION)
  • TABLE 254. NORTH AMERICA BIOPSY DEVICES MARKET SIZE, BY VACUUM ASSISTED, 2025-2032 (USD MILLION)
  • TABLE 255. NORTH AMERICA BIOPSY DEVICES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 256. NORTH AMERICA BIOPSY DEVICES MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 257. NORTH AMERICA BIOPSY DEVICES MARKET SIZE, BY BREAST, 2018-2024 (USD MILLION)
  • TABLE 258. NORTH AMERICA BIOPSY DEVICES MARKET SIZE, BY BREAST, 2025-2032 (USD MILLION)
  • TABLE 259. NORTH AMERICA BIOPSY DEVICES MARKET SIZE, BY KIDNEY, 2018-2024 (USD MILLION)
  • TABLE 260. NORTH AMERICA BIOPSY DEVICES MARKET SIZE, BY KIDNEY, 2025-2032 (USD MILLION)
  • TABLE 261. NORTH AMERICA BIOPSY DEVICES MARKET SIZE, BY LIVER, 2018-2024 (USD MILLION)
  • TABLE 262. NORTH AMERICA BIOPSY DEVICES MARKET SIZE, BY LIVER, 2025-2032 (USD MILLION)
  • TABLE 263. NORTH AMERICA BIOPSY DEVICES MARKET SIZE, BY LUNG, 2018-2024 (USD MILLION)
  • TABLE 264. NORTH AMERICA BIOPSY DEVICES MARKET SIZE, BY LUNG, 2025-2032 (USD MILLION)
  • TABLE 265. NORTH AMERICA BIOPSY DEVICES MARKET SIZE, BY PROSTATE, 2018-2024 (USD MILLION)
  • TABLE 266. NORTH AMERICA BIOPSY DEVICES MARKET SIZE, BY PROSTATE, 2025-2032 (USD MILLION)
  • TABLE 267. NORTH AMERICA BIOPSY DEVICES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 268. NORTH AMERICA BIOPSY DEVICES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 269. LATIN AMERICA BIOPSY DEVICES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 270. LATIN AMERICA BIOPSY DEVICES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 271. LATIN AMERICA BIOPSY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 272. LATIN AMERICA BIOPSY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 273. LATIN AMERICA BIOPSY DEVICES MARKET SIZE, BY CORE NEEDLE, 2018-2024 (USD MILLION)
  • TABLE 274. LATIN AMERICA BIOPSY DEVICES MARKET SIZE, BY CORE NEEDLE, 2025-2032 (USD MILLION)
  • TABLE 275. LATIN AMERICA BIOPSY DEVICES MARKET SIZE, BY ENDOSCOPIC, 2018-2024 (USD MILLION)
  • TABLE 276. LATIN AMERICA BIOPSY DEVICES MARKET SIZE, BY ENDOSCOPIC, 2025-2032 (USD MILLION)
  • TABLE 277. LATIN AMERICA BIOPSY DEVICES MARKET SIZE, BY FINE NEEDLE ASPIRATION, 2018-2024 (USD MILLION)
  • TABLE 278. LATIN AMERICA BIOPSY DEVICES MARKET SIZE, BY FINE NEEDLE ASPIRATION, 2025-2032 (USD MILLION)
  • TABLE 279. LATIN AMERICA BIOPSY DEVICES MARKET SIZE, BY VACUUM ASSISTED, 2018-2024 (USD MILLION)
  • TABLE 280. LATIN AMERICA BIOPSY DEVICES MARKET SIZE, BY VACUUM ASSISTED, 2025-2032 (USD MILLION)
  • TABLE 281. LATIN AMERICA BIOPSY DEVICES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 282. LATIN AMERICA BIOPSY DEVICES MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 283. LATIN AMERICA BIOPSY DEVICES MARKET SIZE, BY BREAST, 2018-2024 (USD MILLION)
  • TABLE 284. LATIN AMERICA BIOPSY DEVICES MARKET SIZE, BY BREAST, 2025-2032 (USD MILLION)
  • TABLE 285. LATIN AMERICA BIOPSY DEVICES MARKET SIZE, BY KIDNEY, 2018-2024 (USD MILLION)
  • TABLE 286. LATIN AMERICA BIOPSY DEVICES MARKET SIZE, BY KIDNEY, 2025-2032 (USD MILLION)
  • TABLE 287. LATIN AMERICA BIOPSY DEVICES MARKET SIZE, BY LIVER, 2018-2024 (USD MILLION)
  • TABLE 288. LATIN AMERICA BIOPSY DEVICES MARKET SIZE, BY LIVER, 2025-2032 (USD MILLION)
  • TABLE 289. LATIN AMERICA BIOPSY DEVICES MARKET SIZE, BY LUNG, 2018-2024 (USD MILLION)
  • TABLE 290. LATIN AMERICA BIOPSY DEVICES MARKET SIZE, BY LUNG, 2025-2032 (USD MILLION)
  • TABLE 291. LATIN AMERICA BIOPSY DEVICES MARKET SIZE, BY PROSTATE, 2018-2024 (USD MILLION)
  • TABLE 292. LATIN AMERICA BIOPSY DEVICES MARKET SIZE, BY PROSTATE, 2025-2032 (USD MILLION)
  • TABLE 293. LATIN AMERICA BIOPSY DEVICES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 294. LATIN AMERICA BIOPSY DEVICES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 295. EUROPE, MIDDLE EAST & AFRICA BIOPSY DEVICES MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 296. EUROPE, MIDDLE EAST & AFRICA BIOPSY DEVICES MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 297. EUROPE, MIDDLE EAST & AFRICA BIOPSY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 298. EUROPE, MIDDLE EAST & AFRICA BIOPSY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 299. EUROPE, MIDDLE EAST & AFRICA BIOPSY DEVICES MARKET SIZE, BY CORE NEEDLE, 2018-2024 (USD MILLION)
  • TABLE 300. EUROPE, MIDDLE EAST & AFRICA BIOPSY DEVICES MARKET SIZE, BY CORE NEEDLE, 2025-2032 (USD MILLION)
  • TABLE 301. EUROPE, MIDDLE EAST & AFRICA BIOPSY DEVICES MARKET SIZE, BY ENDOSCOPIC, 2018-2024 (USD MILLION)
  • TABLE 302. EUROPE, MIDDLE EAST & AFRICA BIOPSY DEVICES MARKET SIZE, BY ENDOSCOPIC, 2025-2032 (USD MILLION)
  • TABLE 303. EUROPE, MIDDLE EAST & AFRICA BIOPSY DEVICES MARKET SIZE, BY FINE NEEDLE ASPIRATION, 2018-2024 (USD MILLION)
  • TABLE 304. EUROPE, MIDDLE EAST & AFRICA BIOPSY DEVICES MARKET SIZE, BY FINE NEEDLE ASPIRATION, 2025-2032 (USD MILLION)
  • TABLE 305. EUROPE, MIDDLE EAST & AFRICA BIOPSY DEVICES MARKET SIZE, BY VACUUM ASSISTED, 2018-2024 (USD MILLION)
  • TABLE 306. EUROPE, MIDDLE EAST & AFRICA BIOPSY DEVICES MARKET SIZE, BY VACUUM ASSISTED, 2025-2032 (USD MILLION)
  • TABLE 307. EUROPE, MIDDLE EAST & AFRICA BIOPSY DEVICES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 308. EUROPE, MIDDLE EAST & AFRICA BIOPSY DEVICES MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 309. EUROPE, MIDDLE EAST & AFRICA BIOPSY DEVICES MARKET SIZE, BY BREAST, 2018-2024 (USD MILLION)
  • TABLE 310. EUROPE, MIDDLE EAST & AFRICA BIOPSY DEVICES MARKET SIZE, BY BREAST, 2025-2032 (USD MILLION)
  • TABLE 311. EUROPE, MIDDLE EAST & AFRICA BIOPSY DEVICES MARKET SIZE, BY KIDNEY, 2018-2024 (USD MILLION)
  • TABLE 312. EUROPE, MIDDLE EAST & AFRICA BIOPSY DEVICES MARKET SIZE, BY KIDNEY, 2025-2032 (USD MILLION)
  • TABLE 313. EUROPE, MIDDLE EAST & AFRICA BIOPSY DEVICES MARKET SIZE, BY LIVER, 2018-2024 (USD MILLION)
  • TABLE 314. EUROPE, MIDDLE EAST & AFRICA BIOPSY DEVICES MARKET SIZE, BY LIVER, 2025-2032 (USD MILLION)
  • TABLE 315. EUROPE, MIDDLE EAST & AFRICA BIOPSY DEVICES MARKET SIZE, BY LUNG, 2018-2024 (USD MILLION)
  • TABLE 316. EUROPE, MIDDLE EAST & AFRICA BIOPSY DEVICES MARKET SIZE, BY LUNG, 2025-2032 (USD MILLION)
  • TABLE 317. EUROPE, MIDDLE EAST & AFRICA BIOPSY DEVICES MARKET SIZE, BY PROSTATE, 2018-2024 (USD MILLION)
  • TABLE 318. EUROPE, MIDDLE EAST & AFRICA BIOPSY DEVICES MARKET SIZE, BY PROSTATE, 2025-2032 (USD MILLION)
  • TABLE 319. EUROPE, MIDDLE EAST & AFRICA BIOPSY DEVICES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 320. EUROPE, MIDDLE EAST & AFRICA BIOPSY DEVICES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 321. EUROPE BIOPSY DEVICES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 322. EUROPE BIOPSY DEVICES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 323. EUROPE BIOPSY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 324. EUROPE BIOPSY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 325. EUROPE BIOPSY DEVICES MARKET SIZE, BY CORE NEEDLE, 2018-2024 (USD MILLION)
  • TABLE 326. EUROPE BIOPSY DEVICES MARKET SIZE, BY CORE NEEDLE, 2025-2032 (USD MILLION)
  • TABLE 327. EUROPE BIOPSY DEVICES MARKET SIZE, BY ENDOSCOPIC, 2018-2024 (USD MILLION)
  • TABLE 328. EUROPE BIOPSY DEVICES MARKET SIZE, BY ENDOSCOPIC, 2025-2032 (USD MILLION)
  • TABLE 329. EUROPE BIOPSY DEVICES MARKET SIZE, BY FINE NEEDLE ASPIRATION, 2018-2024 (USD MILLION)
  • TABLE 330. EUROPE BIOPSY DEVICES MARKET SIZE, BY FINE NEEDLE ASPIRATION, 2025-2032 (USD MILLION)
  • TABLE 331. EUROPE BIOPSY DEVICES MARKET SIZE, BY VACUUM ASSISTED, 2018-2024 (USD MILLION)
  • TABLE 332. EUROPE BIOPSY DEVICES MARKET SIZE, BY VACUUM ASSISTED, 2025-2032 (USD MILLION)
  • TABLE 333. EUROPE BIOPSY DEVICES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 334. EUROPE BIOPSY DEVICES MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 335. EUROPE BIOPSY DEVICES MARKET SIZE, BY BREAST, 2018-2024 (USD MILLION)
  • TABLE 336. EUROPE BIOPSY DEVICES MARKET SIZE, BY BREAST, 2025-2032 (USD MILLION)
  • TABLE 337. EUROPE BIOPSY DEVICES MARKET SIZE, BY KIDNEY, 2018-2024 (USD MILLION)
  • TABLE 338. EUROPE BIOPSY DEVICES MARKET SIZE, BY KIDNEY, 2025-2032 (USD MILLION)
  • TABLE 339. EUROPE BIOPSY DEVICES MARKET SIZE, BY LIVER, 2018-2024 (USD MILLION)
  • TABLE 340. EUROPE BIOPSY DEVICES MARKET SIZE, BY LIVER, 2025-2032 (USD MILLION)
  • TABLE 341. EUROPE BIOPSY DEVICES MARKET SIZE, BY LUNG, 2018-2024 (USD MILLION)
  • TABLE 342. EUROPE BIOPSY DEVICES MARKET SIZE, BY LUNG, 2025-2032 (USD MILLION)
  • TABLE 343. EUROPE BIOPSY DEVICES MARKET SIZE, BY PROSTATE, 2018-2024 (USD MILLION)
  • TABLE 344. EUROPE BIOPSY DEVICES MARKET SIZE, BY PROSTATE, 2025-2032 (USD MILLION)
  • TABLE 345. EUROPE BIOPSY DEVICES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 346. EUROPE BIOPSY DEVICES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 347. MIDDLE EAST BIOPSY DEVICES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 348. MIDDLE EAST BIOPSY DEVICES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 349. MIDDLE EAST BIOPSY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 350. MIDDLE EAST BIOPSY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 351. MIDDLE EAST BIOPSY DEVICES MARKET SIZE, BY C